5-(3-ethoxypropyl)-4-methyl-2-(4-phenyl-1,3-thiazol-2-yl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione | 1217798-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 5-(3-ethoxypropyl)-4-methyl-2-(4-phenyl-1,3-thiazol-2-yl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione
• 英文别名: 5-(3-ethoxypropyl)-4-methyl-2-(4-phenyl-1,3-thiazol-2-yl)-1H-pyrazolo[4,3-c]pyridine-3,6-dione
• CAS: 1217798-41-8
• 化学式: C₂₁H₂₂N₄O₃S
• 分子量: 410.497
• InChiKey: HXQMSKGSKNJJLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
  申请人：GENKYO TEX SA

  公开号：EP2166010A1

  公开（公告）日：2010-03-24

  The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式(I)的吡唑吡啶衍生物，其药物组成物以及它们用于治疗和/或预防与烟酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状的用途。
• PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  申请人：Page Patrick

  公开号：US20110269757A1

  公开（公告）日：2011-11-03

  The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式（I）的吡唑吡啶衍生物，其制药组合物以及它们用于治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）有关的疾病或症状的用途。
• US9096588B2
  申请人：——

  公开号：US9096588B2

  公开（公告）日：2015-08-04
• US9974791B2
  申请人：——

  公开号：US9974791B2

  公开（公告）日：2018-05-22
• [EN] PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLO PYRIDINE TENANT LIEU D'INHIBITEURS DE NADPH OXYDASE
  申请人：GENKYOTEX SA

  公开号：WO2010035221A1

  公开（公告）日：2010-04-01

  The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).